(SMART), it has been shown that hsCRP and IL-6 levels are associated with HIV viral replication and CVD and all-cause mortality risk [8 ,14 ,46] . In SMART, higher levels of hsCRP and IL-6 at baseline were strongly associated with increased risk for mortality both over the short-them and long-term (CVD and non-CVD related) [14 ,46] . A major limitation of these data is the ability to quantify the risk for a CVD event associated with absolute differences or changes in biomarker levels, as they involve case-control studies. In a separate data registry study [15 ] of HIV-infected patients, higher CRP levels were associated with increased risk for myocardial infarction. Additional longitudinal studies of HIVinfected persons with suppressed HIV RNA levels are needed to validate and refine these risk associations.
Interruption of ART among patients with a suppressed viral load in SMART was associated with a rapid rise in IL-6 levels that correlated with HIV RNA levels [14 ] . In a subgroup of SMART participants that were naïve to or off ART (for at least 6 months) at enrollment, biomarker changes were examined for those starting ART compared with those randomized to defer ART [10 ] . In this study, early versus delayed ART was not associated with significant improvements in IL-6 or hsCRP. In general, reports of changes in either hsCRP or IL-6 after starting ART have been inconsistent, and most studied have lacked a comparison group of participants not taking ART [12,17,20 ,21,26 ] . Furthermore, levels of hsCRP and IL-6 among SMART participants with a suppressed viral load were approximately 40-60% higher than matched controls from the general population [from the Multi-Ethnic Study of Atherosclerosis (MESA) and the Coronary Artery Risk Development in Young Adults (CARDIA) study] [8 ] . Cumulatively, these data suggest that any improvement in inflammatory markers with ART use is incomplete, and there is a need for adjunct anti-inflammatory treatments for individuals with HIV infection.
Finally, any potential anti-inflammatory benefits of ART may also differ by the specific antiretroviral components [47, 48] . In a baseline cross-sectional comparison of SMART participants, use of abacavir versus other nucleoside reverse transcriptase inhibitors (NRTIs) was associated with 27 and 16% higher levels of hsCRP and IL-6, respectively [48] . However, to date, longitudinal data have been unable to replicate a significant effect of abacavir exposure specifically for elevations in inflammatory markers [17, [49] [50] [51] .
Markers of thrombotic activity
Higher levels of fibrinogen and D-dimer (a fibrin split product) have been associated with increased risk for allcause mortality both in HIV-infected and uninfected populations [14 ,19 ,52,53] . In SMART, D-dimer levels at baseline were strongly associated with risk of death [odds ratio (OR) for 4th/1st quartile 41.2, P < 0.0001] in adjusted models [14 ] . In this analysis, associations were present for CVD and non-CVD death, and for persons on and off ART. Changes in D-dimer levels after stopping or starting ART are associated with the degree of HIV viral replication or suppression, respectively [10 ,14 ,20 , 21] . Despite this, D-dimer levels remain 49% elevated in SMART participants with HIV suppression compared 512 Biomarkers of outcomes of disease, treatment and complications [8 ,9] Data are inconsistent [8 ,9,10 ,11] Data are inconsistent [10 ,12,13] CVD and all-cause mortality [14 ,15 ] IL- 6 62-152% higher [8 ,16] Correlated with VL after stopping ART [14 ] Data are inconsistent [10 ,17] CVD and all-cause mortality [14 ] Thrombotic Fibrinogen 8% higher in men [18] Correlated with VL [19 ] No longitudinal data [18] All-cause mortality [19 ] D-dimer 71-94% higher [8 ,16] Correlated with VL-steady state and after stopping ART [8 ,10 ,14 ] Improved levels, but incomplete [8 ,10 ,20 ,21] CVD and all-cause mortality [14 ,22 ] Endothelial (dyes)function Endothelial adhesion molecules (sICAM-1/sVCAM-1)
Typically >40% higher [16, 21, 23, 24] Correlated with VL after stopping ART [20 ,25] Improved levels reported [12,20 ,21,26 ] CVD (sVCAM-1) [22 ] Cardiac function NT-proBNP Unknown Unknown Unknown CVD [27 ] Lipids HDL particles 13-21% lower [16, 28] Inversely correlated with VL after stopping ART [29 ] Unknown CVD [29 ] ART, antiretroviral therapy; CRP, C-Reactive Protein; CVD, cardiovascular disease; HDL, high-density lipoprotein; IL-6, interleukin-6; NT-proBNP, Nterminal-pro-brain-type natriuretic peptide; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion moledule-1; VL, HIV viral load.
with uninfected controls from MESA [8 ] . In the Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM), fibrinogen levels in men were 8% higher compared with uninfected controls from the CAR-DIA study [18] . Follow-up analyses in FRAM have recently reported an increased risk of all cause mortality (OR 2.57 for 3rd/1st tertile, P < 0.001) independent of hsCRP levels, though the risk gradient declined with higher CD4 cell counts [19 ] . When the influence of treatment was examined in FRAM, fibrinogen levels were 11% higher for participants taking a protease inhibitor, and 10% lower for those taking a nonnucleoside reverse transcriptase inhibitor (NNRTI), when compared with uninfected controls [18] . The influence of specific antiretrovirals on changes in fibrinogen and D-dimer levels requires further study.
It is worth noting that D-dimer and fibrinogen are nonspecific markers, which primarily reflect increased activity in the thrombotic process and may be elevated in response to inflammatory stimuli. In terms of understanding the mechanisms driving thrombogenesis in this context, more research is needed to identify the specific steps in coagulation and fibrinolysis pathways that are most affected by HIV infection and/or its treatment. An increase in procoagulant factors (e.g., antiphospholipid antibodies), decrease in anticoagulant factors (e.g., deficiencies in protein C or S), and platelet activation have all been reported with HIV infection [54] [55] [56] [57] [58] [59] [60] . Another possibility is that HIV infection and/or immune activation increases expression of tissue factor on endothelial cells (reviewed below) or leukocytes, thereby upregulating the 'extrinsic' coagulation pathway [61, 62 ] . In a case-control study of 127 HIV-infected patients, soluble tissue factor was elevated approximately 4 months prior to a CVD event when compared with controls who did not have an event [22 ] . In another recent report, HIVinfected persons were found to have more tissue factor expression on circulating blood mononuclear cells compared with uninfected controls [62 ] . In this study, the expression of tissue factor correlated with HIV RNA levels, the proportion of CD8 þ T cells expressing immune activation markers, and with D-dimer levels [62 ] .
Markers of vascular function
Vascular damage related to HIV replication and HIV therapy can be assessed via markers of endothelial function, injury, and/or activation. Following injury, endothelial cells express various adhesion markers that may trigger an inflammatory response, adhesion and transmigration of leukocytes, platelet aggregation, and activate blood clotting [63] [64] [65] . Endothelial biomarkers, such as soluble intercellular and vascular cell adhesion molecule (sICAM-1 and sVCAM-1), selectins (E-selectin and P-selectin), and molecules involved in coagulation and fibrinolysis [von Willebrand factor (vWF), thrombomodulin, and tissue-plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1)], are associated with CVD risk and all-cause mortality in the general population [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] . Endothelial biomarkers are consistently elevated in HIV-infected compared with uninfected individuals [16, 23, 76, 77] . In a cross-sectional study of 73 HIV-infected individuals, sVCAM-1 levels were associated with subclinical atherosclerosis assessed by ultrasound estimates of carotid intima-media thickness [77] .
In the context of treatment interruption, endothelial adhesion markers (sICAM-1, sVCAM-1 and P-selectin) increase, and the change in sVCAM-1 specifically has been associated with increases in HIV viral replication [20 ,25] . In one of these treatment interruption studies, sVCAM-1 levels remained elevated despite HIV suppression 6 weeks after restarting ART (n ¼ 21), compared with those randomized to persistent viral suppression (n ¼ 21) throughout the study period [25] . Although many studies have demonstrated improvements in some endothelial biomarkers after starting ART, not all markers improve in all studies [12,13,20 ,21,25,76] . Furthermore, a differential effect of specific antiretrovirals (e.g., protease inhibitors or abacavir versus other therapy) on endothelial biomarkers has not been a focus of clinical studies to date [13, 21, [49] [50] [51] . Cumulatively, these data emphasize that larger studies with longer follow-up are needed to validate which endothelial biomarkers can be used for early detection of CVD in HIV-infected patients.
Although more reflective of cardiac rather than endothelial dysfunction, a recent analysis from SMART demonstrated that higher baseline levels of N-terminal-pro-brain-type natriuretic peptide (NT-proBNP) were independently associated with greater risk for CVD (OR 4th/1st quartile ¼ 1.4), even after adjusting for hsCRP, IL-6 and D-dimer levels (OR 1.2) [27 ] . NT-proBNP is released from myocytes and reflects increased ventricular stretch and wall tension. It remains unclear how HIV or ART independently influence NT-proBNP levels. Studies such as this, which consider novel markers, are important to better understand the physiology and pathogenesis of HIV-associated cardiovascular dysfunction.
Lipids and lipoproteins
Both HIV and exposure to ART result in proatherogenic changes in blood lipids. Among men in the Multicenter AIDS Cohort (MACS) who were followed pre-HIV and post-HIV infection, all serum lipid levels declined after HIV seroconversion [78] . Subsequently, initiation of ART among HIV-infected patients in MACS led to increases in total and low-density lipoprotein cholesterol (LDL-C) above preinfection levels, whereas high density lipoprotein cholesterol (HDL-C) remained approximately 10 mg/dl below preinfection levels [78] . Furthermore, levels of HDL-C are inversely related to HIV viral load and increase more after starting NNRTI versus protease inhibitor-based [79, 80] . Thus, HIV infection and ART exposure adversely influence the total cholesterol to HDL-C ratio, one of the strongest predictors of coronary heart disease risk in terms of serum lipid measures [81, 82] .
NMR (nuclear magnetic resonance) spectroscopy allows characterization of the lipid fractions in blood beyond what is represented in traditional measures of cholesterol by 'counting' numbers of lipoprotein particles and assessing their size [83] . Changes in the number of HDL particles, or concentration, appear to be informative for CVD event risk but may not be apparent when measuring traditional HDL-C [84, 85] . In a cross-sectional study [16] , total HDL particle concentration was 21% lower in patients with untreated HIV infection compared with uninfected controls, and this was primarily due to lower numbers of large and small HDL particles. In this same study, small HDL particle numbers were inversely correlated with levels of IL-6, D-dimer and sICAM-1 [16] . In SMART, lower total HDL particle concentration was independently associated with risk for CVD (OR for 4th/1st quartile 0.47, P ¼ 0.001), even after additional adjustment for IL-6 (OR ¼ 0.50, P ¼ 0.02) or D-dimer (OR ¼ 0.49, P ¼ 0.02) [29 ] . Furthermore, among SMART participants with suppressed viral load, the decline in total HDL particles was associated with HIV RNA level 1 month after stopping ART [29 ] . In a crosssectional analysis of lipoprotein particles in MACS, total HDL particles remained lower in HIV-infected participants receiving ART compared with uninfected controls [28] . In summary, proatherogenic changes in HDL associated with HIV infection may not be fully corrected by ART, and assessment of HDL particle number provides clinically relevant information for CVD risk in HIVinfected patients.
Conclusion
CVD biomarkers previously validated in the general population, including CRP, IL-6, fibrinogen and D-dimer, are present at higher levels among HIV-infected compared with uninfected persons, and remain strongly predictive for CVD and mortality risk in HIV studies. Data from treatment interruption studies suggest that HIV replication may contribute to premature atherosclerosis, in part, through greater inflammation, thrombotic activity and damage to endothelial surfaces. These findings are summarized in Fig. 1 . Starting ART appears to be associated with an incomplete improvement in some, but not all, CVD biomarkers and this effect may vary by the specific antiretroviral.
An important goal of future research should be to clarify whether candidate CVD biomarkers improve risk stratification beyond traditional and HIV-related risk factors. Ultimately, whether these plasma biomarkers are mediators of a disease process or markers of clinical risk markers without direct causality, treatments that lead to lower levels may have a profound impact on mortality risk for persons with HIV infection.
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